Loading stock data…
KOD
$31.06+1.45 (+4.90%)
Market ClosedLast close Jun 9
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kodiak Sciences Inc. in the Healthcare sector is trading at $31.06 with a market capitalization of $2.1B. Wall Street consensus targets $62.67 (6 analysts), implying a +101.8% move over the next 12 months. The stock is currently 35% below its 52-week high of $47.84, remaining 21.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +101.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$31.06
Potential Downside
0%
Whystock Fair Value$31.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$62.67+101.8%
Range$56.00 – $80.00
Fundamentals
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular end...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-205.76%
Volume
Today's trading volume
689,082
Recent News
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans
Kodiak Sciences recently presented at the Jefferies Global Healthcare Conference in New York, highlighting earlier positive Phase III GLOW2 data for its ophthalmology candidate Zenkuda in diabetic retinopathy and plans to accelerate regulatory filings. A key insight is that Kodiak’s combination of strong late-stage clinical results, an advancing pipeline and a debt-free balance sheet could meaningfully reshape its profile as it moves closer to potential commercialization. Next, we’ll examine...
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.